Playback speed
10 seconds
SGLT-2 Inhibitors & GLP-1 RAs in CV Risk: What Are the Beneficial Effects on Reducing CVD Events?
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
By
Cardiometabolic Health Congress (CMHC)
FEATURING
Robert Eckel
184 views
January 15, 2021
Comments 0
Login to view comments.
Click here to Login